Chemomab Therapeutics Ltd. (CMMB) Fair Value 2026

CMMB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-28, Chemomab Therapeutics Ltd. (CMMB) trades at $2.71. QOC: 4.7/10. Value Trap Risk: 43/100 (WARN). 0/13 models active.

Key Facts

Ticker
CMMB
Price
$2.71
Quality Score
4.7/10
Value Trap Risk
43/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CMMB?

0 Intrinsic Value Models vs. Current Price ($2.71)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Chemomab Therapeutics Ltd. (CMMB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Chemomab Therapeutics Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CMMB?

0 of 13 models are currently active for CMMB. See which stocks rank higher →

How Does CMMB Rank in Biotechnology?

Among 625 Biotechnology stocks, CMMB ranks #390 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Chemomab Therapeutics Ltd. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating CMMB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CMMB a Value Trap?

CirclFi's Value Trap algorithm assigns CMMB a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Chemomab Therapeutics Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Chemomab Therapeutics Ltd.'s fundamental quality profile registers 4.7/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CMMB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Chemomab Therapeutics Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BNTCBenitec Biopharma Inc.QOC 4.7NXTCNextCure, Inc.QOC 4.7VANIVivani Medical, Inc.QOC 4.7TYRATyra Biosciences, Inc.QOC 4.7TELOTelomir Pharmaceuticals, Inc.QOC 4.8ENGNenGene Therapeutics Inc.QOC 4.7TPSTTempest Therapeutics, Inc.QOC 3.9WVEWave Life Sciences, Inc.QOC 6.6IMMPImmutep LimitedQOC 5.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BNTC · NXTC · VANI · TYRA · TELO · ENGN · TPST · WVE · IMMP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CMMB?

6 companies across all industries closest to CMMB’s Quality of Company score of 4.7/10.

OBAIOur Bond, Inc.QOC 4.7RYESRise Gold Corp.QOC 4.7BEATHeartBeam, Inc.QOC 4.7IPSTIP Strategy Holdings, Inc.QOC 4.7BTDRBitdeer Technologies GroupQOC 4.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: OBAI · RYES · BEAT · IPST · BTDR · NVDA

Where Does CMMB Sit in CirclFi's Biotechnology Rankings?

CMMB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Chemomab Therapeutics Ltd.’s Valuation?

What is Chemomab Therapeutics Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Chemomab Therapeutics Ltd. (CMMB). The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CMMB overvalued or undervalued right now?

At $2.71, 0 of 0 active models suggest CMMB may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Chemomab Therapeutics Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 4.7 mean for CMMB?

Chemomab Therapeutics Ltd.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CMMB?

CirclFi analyzes CMMB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CMMB a value trap in 2026?

Chemomab Therapeutics Ltd.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Chemomab Therapeutics Ltd. (CMMB) a Quality of Company score of 4.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CMMB/ · Methodology
Primary sources for this CMMB valuation
  • Financial statements: Chemomab Therapeutics Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001534248) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CMMB as of ; valuations recomputed .